文献速递神经核医学肿瘤 PET/CT放射性药物与辐射防护

脑淀粉样蛋白显像的全球经验

Global experience in brain amyloid imaging.
PubMed 文献 · Semin Nucl Med · 2025-04-12

本文综述脑淀粉样蛋白显像的全球应用经验。全球应用因医疗基础设施、费用与监管差异而不均衡,北美与欧洲领先,中低收入国家可及性有限;AI辅助分析与新一代示踪剂是发展趋势。

要点

  • 高收入国家淀粉样蛋白PET用于鉴别非典型痴呆及筛选抗淀粉样蛋白治疗患者。

核心结论

  • 淀粉样蛋白PET仍是诊断和理解阿尔茨海默病及相关神经退行性疾病的关键工具,但其全球应用因医疗基础设施、费用与监管框架差异而不均衡。
  • 研究正聚焦于将淀粉样蛋白PET与tau PET、脑脊液分析和血浆检测等其他生物标志物整合,以提高诊断准确性。
  • 应对临床前筛查的伦理关切并确保淀粉样蛋白PET的公平可及,对优化其在全球神经病学和核医学中的作用至关重要。

研究设计与样本

  • 本文为综述,检索范围原文未报告。

主要发现

  • 在高收入国家,淀粉样蛋白PET越来越多地用于临床流程,尤其用于鉴别非典型痴呆病例和为阿杜那单抗(aducanumab)与仑卡奈单抗(lecanemab)等抗淀粉样蛋白治疗筛选患者。
  • 尽管淀粉样蛋白PET具有高敏感性和特异性,其在认知正常但存在淀粉样蛋白蓄积个体中的临床效用仍存挑战。
  • 淀粉样蛋白PET研究与实施存在地理差异,北美和欧洲领先,而中低收入国家可及性仍有限。

关键数值与推荐

  • 原文未报告诊断阈值、定量标准或推荐等级。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出,尽管淀粉样蛋白PET具有高敏感性和特异性,其在认知正常但存在淀粉样蛋白蓄积个体中的临床效用仍存挑战。
  • 原文指出,全球应用因医疗基础设施、费用与监管框架的差异而不均衡,中低收入国家可及性仍有限。
  • 原文指出,临床前筛查相关伦理关切与确保淀粉样蛋白PET公平可及是需应对的问题。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Brain amyloid imaging has become a crucial tool in diagnosing and understanding Alzheimer's disease (AD) and related neurodegenerative disorders. The introduction of amyloid positron emission tomography (PET) with [¹¹C]Pittsburgh Compound-B ([¹¹C]PiB) in the early 2000s marked a breakthrough in visualizing amyloid-β (Aβ) deposition in vivo. Subsequent development of ¹⁸F-labeled tracers, such as [¹⁸F]florbetapir, [¹⁸F]flutemetamol, and [¹⁸F]florbetaben, improved accessibility and extended imaging capabilities. However, global adoption remains uneven due to disparities in healthcare infrastructure, costs, and regulatory frameworks. In high-income countries, amyloid PET is increasingly used in clinical workflows, particularly for differentiating atypical dementia cases and selecting patients for anti-amyloid therapies like aducanumab and lecanemab. Despite its high sensitivity and specificity, challenges persist regarding its clinical utility, particularly in cognitively normal individuals with amyloid accumulation. Research is focusing on integrating amyloid PET with other biomarkers-tau PET, cerebrospinal fluid analysis, and plasma assays-to improve diagnostic accuracy. Geographical variations in amyloid PET research and implementation reveal North America and Europe as leaders, while access remains limited in low- and middle-income countries. Efforts such as the Worldwide Alzheimer's Disease Neuroimaging Initiative aim to enhance global standardization and accessibility. Emerging trends in artificial intelligence (AI)-assisted imaging analysis and next-generation tracers promise further improvements. Addressing ethical concerns related to preclinical screening and ensuring equitable access to amyloid PET are critical for optimizing its role in neurology and nuclear medicine worldwide.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Filippi L, Schillaci O. Global experience in brain amyloid imaging. Semin Nucl Med. 2025. PMID: 40222870. doi:10.1053/j.semnuclmed.2025.03.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。